醒脑静联合依达拉奉对急性脑出血患者神经功能及 血清 HMGB-1、TGF-β1 、ICAM-1 水平的影响

Effects of Xingnaojing combined with edaravone on neurological function and serum HMGB-1,TGF-β1 and ICAM-1 levels in patients with acute cerebral hemorrhage

目的探讨醒脑静联合依达拉奉对急性脑出血患者神经功能及血清高迁移率族蛋白B-1(HMGB-1)、转化生长因子-β_(1)(TGF-β_(1))、细胞间黏附分子-1(ICAM-1)水平的影响。方法选取2018-2022年收治的128例急性脑出血患者为研究对象,按照随机数字表法将其分为研究组和对照组,各64例。对照组给予依达拉奉治疗,研究组给予醒脑静联合依达拉奉治疗。比较两组的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的血肿体积、绝对水肿体积、相对血肿体积、美国国立卫生院卒中量表(NIHSS)评分、HMGB-1、TGF-β_(1)、ICAM-1、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平均降低,格拉斯哥昏迷量表(GCS)评分均升高,且研究组优于对照组(P<0.05)。结论醒脑静联合依达拉奉能显著缩小急性脑出血患者的脑部血肿体积,减轻炎症反应,促进神经功能恢复,提高临床疗效。

Objective To investigate the effects of Xingnaojing combined with edaravone on neurological function and serum high mobility group box-1 protein(HMGB-1),transforming growth factor-β_(1)(TGF-β_(1))and intercellular adhesion molecule-1(ICAM-1)levels in patients with acute cerebral hemorrhage.Methods A total of 128 patients with acute cerebral hemorrhage admitted from 2018 to 2022 were selected as the research objects and divided into study group and control group according to the random number table method,with 64 cases in each group.The control group was treated with edaravone,and the study group was treated with Xingnaojing combined with edaravone.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the hematoma volume,absolute edema volume,relative hematoma volume,the National Institutes of Health Stroke Scale(NIHSS)score,HMGB-1,TGF-β_(1),ICAM-1,tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)levels in the two groups decreased,the Glasgow Coma Scale(GCS)score increased,and those in the study group were better than the control group(P<0.05).Conclusion Xingnaojing combined with edaravone can significantly reduce the volume of brain hematoma in patients with acute cerebral hemorrhage,reduce inflammation,promote the recovery of neurological function,and improve clinical efficacy.